Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support

[1]  I. Apostolova,et al.  Feasibility of 99mTc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients , 2022, The Journal of Nuclear Medicine.

[2]  H. G. van der Poel,et al.  Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. , 2022, European urology.

[3]  H. G. van der Poel,et al.  Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. , 2022, European urology.

[4]  C. Zamboglou,et al.  Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series. , 2021, European urology focus.

[5]  T. Holland-Letz,et al.  Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  H. G. van der Poel,et al.  Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. , 2020, European urology.

[7]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[8]  A. Mottrie,et al.  Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. , 2020, European urology.

[9]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[10]  H. Heinzer,et al.  Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. , 2019, European urology focus.

[11]  H. G. van der Poel,et al.  Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. , 2019, European urology.

[12]  R. V. D. van den Bergh,et al.  Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. , 2019, European urology.

[13]  Kristina Schwamborn,et al.  99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. , 2019, European urology.

[14]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[15]  W. Everaerts,et al.  Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. , 2019, European urology oncology.

[16]  M. Graefen,et al.  Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. , 2019, European urology focus.

[17]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Samaratunga,et al.  Initial multicentre experience of 68gallium‐PSMA PET/CT guided robot‐assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited , 2017, BJU international.

[19]  C. Stief,et al.  Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients , 2017, Oncotarget.

[20]  K. Schwamborn,et al.  Value of 111In‐prostate‐specific membrane antigen (PSMA)‐radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow‐up , 2017, BJU international.

[21]  M. Schwaiger,et al.  Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy , 2016, The Journal of Nuclear Medicine.

[22]  T. Kuru,et al.  The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer , 2016, Prostate Cancer and Prostatic Diseases.

[23]  V. Flamand,et al.  Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. , 2015, The Journal of urology.

[24]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[25]  F. Montorsi,et al.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. , 2015, European urology.

[26]  C. Stief,et al.  Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. , 2015, The Journal of urology.

[27]  S. Reske,et al.  Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. , 2012, The Journal of urology.

[28]  U. Capitanio,et al.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. , 2011, European urology.

[29]  J. de Pina-Cabral.  World , 2004, Science.

[30]  A. Mottrie,et al.  Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. , 2019, European urology.

[31]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.